ATOSSA THERAPEUTICS, INC. (ATOS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

Atossa announced Q1 2026 financial results on May 8, 2026, with the full press release details not provided in this 8-K excerpt, limiting ability to assess actual financial performance and operational metrics.
The filing is marked as non-material disclosure under Section 18, indicating the company views this earnings announcement as routine earnings communication rather than a material event requiring full liability exposure.
Filing was signed by Mark J. Daniel as CFO, confirming proper authorization and company responsiveness in timely disclosure of quarterly results to shareholders.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-08

All three Class II director nominees were successfully elected with solid support margins (66-87% approval), indicating stable board governance and shareholder confidence in current leadership.
Stockholders approved a reverse stock split authorization (2:1 to 20:1 ratio) with 56% voting in favor, suggesting the board may implement this to maintain Nasdaq listing compliance or improve share price perception.
The advisory vote on executive compensation passed with 77.5% approval despite 2.2M broker non-votes, demonstrating reasonable shareholder alignment with management pay practices.
Ernst & Young LLP was ratified as independent auditor with 90.2% approval and minimal opposition, reflecting confidence in financial reporting and audit oversight.

Filed: 2026-04-16

Atossa Therapeutics has resolved a patent dispute with Intas Pharmaceuticals and Jina Pharmaceuticals, which helps reduce uncertainty around its intellectual property portfolio.
The settlement agreement preserves Atossa's ability to continue developing and commercializing its lead drug candidate Z-endoxifen in key therapeutic areas like oncology, endocrine dysfunction, and muscular dystrophy.
Atossa's two patents related to endoxifen are expected to remain issued and fully enforceable against other third parties upon termination of the pending PTAB proceedings.

Filed: 2026-03-25

Atossa Therapeutics, Inc. reported its Q4 and full-year 2025 financial results, which could provide insights into the company's recent operational and financial performance.
The filing does not mention any material agreements, leadership changes, or other significant corporate events, suggesting a relatively routine quarterly update.
Investors should review the press release (Exhibit 99.1) for details on revenue, expenses, and any updates to the company's development pipeline or guidance.

Filed: 2026-02-20

Atossa Therapeutics entered into a $50 million at-the-market (ATM) equity offering program, allowing the company to issue and sell shares of its common stock from time to time.
The company terminated its prior $50 million ATM equity offering agreement with Jefferies LLC, as it did not undertake any sales under that agreement.
The company intends to use the proceeds from the new ATM offering for clinical development, working capital, and general corporate purposes, potentially including licensing, acquisition, or investment in complementary businesses.

Filed: 2026-02-11

The company issued its 2026 Letter to Shareholders, providing investors with an update on its business and operations.
The letter likely contains information on the company's financial performance, key initiatives, and strategic priorities for the year ahead.
Investors should review the letter for any material developments or changes that could impact the company's future prospects.

Filed: 2026-01-26

Atossa Therapeutics, Inc. approved a 15:1 reverse stock split of its common stock, effective February 2, 2026, to maintain its listing on the Nasdaq Stock Market.
The reverse stock split will proportionately adjust the number of shares subject to outstanding equity awards and the conversion price of the company's Series B Convertible Preferred Stock.
Stockholders approved the reverse stock split proposal at the company's Special Meeting of Stockholders held on January 20, 2026.

Filed: 2026-01-09

Atossa Therapeutics reported an estimated cash and cash equivalents balance of approximately $40 million as of December 31, 2025, indicating a strong financial position.
The company provided an updated corporate presentation, suggesting ongoing progress in its development and regulatory strategy for its lead program, (Z)-Endoxifen.
Atossa Therapeutics mentioned the potential for (Z)-Endoxifen to receive regulatory approval, though the timing and specific indications were not disclosed.

Filed: 2026-01-06

The company has received a 'Study May Proceed' letter from the FDA for a study of metastatic breast cancer, indicating regulatory progress for a key pipeline asset.
The press release announcement on this regulatory milestone suggests the company is making advancements in its clinical development program.
Investors should monitor further updates on the progress and timeline of this breast cancer study, as it could be an important value driver for the company.

Other reports for ATOSSA THERAPEUTICS, INC.

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.